Zainaba Mohamed
Research Subjects
Zainaba Mohamed has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Renuka Priyani Dias
Department of Paediatric Endocrinology and Diabetes, Birmingham Children’s Hospital, Birmingham, UK
2 shared publications - Ajay Thankamony
Cambridge University Hospital NHS Trust, Cambridge, UK
1 shared publication - Amanda Jane Drake
University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
1 shared publication - Amit Allahabadia
Academic Directorate of Diabetes and Endocrinology, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
1 shared publication - Anders Juul
Department of Growth and Reproduction Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark
1 shared publication Andréa T Maciel-Guerra
School of Medical Sciences, Interdisciplinary Group for Study of Sex Determination and Differentiation (GIEDDS), State University of Campinas (Unicamp) , 13083-887 Campinas
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Growth outcomes following recombinant human growth hormone therapy in Zhu–Tokita–Takenouchi–Kim syndrome
Zhu–Tokita–Takenouchi–Kim (ZTTK) syndrome is a rare multisystem developmental disorder caused by heterozygous pathogenic variants in SON. Short stature is common, but data on endocrine function and response to recombinant human growth hormone (rhGH) are limited. We describe a female child with genetically confirmed ZTTK syndrome presenting with profound proportionate short stature, hypotonia, and developmental delay. Insulin-like growth factor 1 (IGF-1) of 91 ng/mL (Systeme international [SI]: 11.9 nmol/L; reference range, 33.6-170.5 ng/mL [SI: 4.4-22.3 nmol/L]) was normal, and peak growth hormone (GH) concentration on arginine stimulation testing was 7.2 ng/mL (SI: 21.6 mIU/L], above the UK diagnostic cutoff for GH deficiency (<6.7 ng/mL [SI: 50% increase in height velocity from baseline (4.3-7.2 cm/year), suggesting a good response to rhGH, with sustained improvement over 2 years (height standard deviation score −4.16 to −3.40). Insulin-like growth factor 1, thyroid function, glucose, and glycated hemoglobin A1c remained normal. No adverse effects were observed. This case demonstrates a clinically significant growth response to rhGH in ZTTK syndrome despite absence of biochemical GH deficiency, supporting a supervised 12-month therapeutic trial.
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Open AccessGrowth outcomes following recombinant human growth hormone therapy in Zhu–Tokita–Takenouchi–Kim syndrome
Zhu–Tokita–Takenouchi–Kim (ZTTK) syndrome is a rare multisystem developmental disorder caused by heterozygous pathogenic variants in SON. Short stature is common, but data on endocrine function and response to recombinant human growth hormone (rhGH) are limited. We describe a female child with genetically confirmed ZTTK syndrome presenting with profound proportionate short stature, hypotonia, and developmental delay. Insulin-like growth factor 1 (IGF-1) of 91 ng/mL (Systeme international [SI]: 11.9 nmol/L; reference range, 33.6-170.5 ng/mL [SI: 4.4-22.3 nmol/L]) was normal, and peak growth hormone (GH) concentration on arginine stimulation testing was 7.2 ng/mL (SI: 21.6 mIU/L], above the UK diagnostic cutoff for GH deficiency (<6.7 ng/mL [SI: 50% increase in height velocity from baseline (4.3-7.2 cm/year), suggesting a good response to rhGH, with sustained improvement over 2 years (height standard deviation score −4.16 to −3.40). Insulin-like growth factor 1, thyroid function, glucose, and glycated hemoglobin A1c remained normal. No adverse effects were observed. This case demonstrates a clinically significant growth response to rhGH in ZTTK syndrome despite absence of biochemical GH deficiency, supporting a supervised 12-month therapeutic trial.
- 7 July 2026
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
Fifteen-minute consultation: A family-centred approach to recognising and managing differences in sex development
Differences of sex development (DSD) comprise a heterogeneous group of congenital conditions affecting urogenital and reproductive development. Variations in sex determination can cause a mismatch between chromosomal, gonadal and phenotypic sex, leading to atypical internal and/or external genitalia. Presentations are varied and most commonly occur in the newborn period and during adolescence. Clinical care is complex and diagnostic pathways may be protracted. Decisions around sex assignment carry ethical considerations and can place a considerable psychological burden on families. This 15-minute guide summarises a practical, stepwise approach for general paediatric and neonatal teams: when to suspect DSD, how to examine and communicate, the first-line investigations to initiate, when/how to escalate to the multidisciplinary DSD service, and how to support families.
- 7 July 2026
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
Fifteen-minute consultation: A family-centred approach to recognising and managing differences in sex development
Differences of sex development (DSD) comprise a heterogeneous group of congenital conditions affecting urogenital and reproductive development. Variations in sex determination can cause a mismatch between chromosomal, gonadal and phenotypic sex, leading to atypical internal and/or external genitalia. Presentations are varied and most commonly occur in the newborn period and during adolescence. Clinical care is complex and diagnostic pathways may be protracted. Decisions around sex assignment carry ethical considerations and can place a considerable psychological burden on families. This 15-minute guide summarises a practical, stepwise approach for general paediatric and neonatal teams: when to suspect DSD, how to examine and communicate, the first-line investigations to initiate, when/how to escalate to the multidisciplinary DSD service, and how to support families.
- Open Access
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
An Unusual Presentation of Severe Hypothyroidism in a Child With Undiagnosed Systemic Lupus Erythematous
Myxedema is increasingly rare in the United Kingdom, particularly among patients already on treatment. We present a case of a 13-year-old girl diagnosed with autoimmune hypothyroidism who was started on 75 µg of levothyroxine by her general practitioner. She was referred to the endocrine clinic after 6 months of treatment for hypothyroidism with 2 months of worsening fatigue, chest pain, peripheral edema, and dyspnea. On hospitalization, the patient’s laboratory tests revealed undetectable free thyroxine level (fT4) and elevated thyrotropin (TSH) greater than 500 μIU/mL (SI: >500 m mIU/L) (reference range, 0.51-4.30 μIU/mL [SI: 0.51-4.30 mIU/L]). She was diagnosed with thyroid myxedema and commenced intravenous (IV) hydrocortisone, IV maintenance fluids, and antibiotics. However, the constellation of signs and symptoms remained perplexing. Further tests revealed a large pericardial effusion, deep vein thrombosis, and nephritis. A multidisciplinary approach confirmed the diagnosis of systemic lupus erythematous (SLE), and the patient was successfully started on rituximab therapy within 5 days of admission. This case illustrates the importance of considering potential underlying diagnoses when assessing patients with hypothyroid crisis, especially when symptoms deviate from the typical clinical presentation. The timely recognition and management of this patient's underlying SLE were crucial in her recovery.
- 3 December 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
Open AccessAn Unusual Presentation of Severe Hypothyroidism in a Child With Undiagnosed Systemic Lupus Erythematous
Myxedema is increasingly rare in the United Kingdom, particularly among patients already on treatment. We present a case of a 13-year-old girl diagnosed with autoimmune hypothyroidism who was started on 75 µg of levothyroxine by her general practitioner. She was referred to the endocrine clinic after 6 months of treatment for hypothyroidism with 2 months of worsening fatigue, chest pain, peripheral edema, and dyspnea. On hospitalization, the patient’s laboratory tests revealed undetectable free thyroxine level (fT4) and elevated thyrotropin (TSH) greater than 500 μIU/mL (SI: >500 m mIU/L) (reference range, 0.51-4.30 μIU/mL [SI: 0.51-4.30 mIU/L]). She was diagnosed with thyroid myxedema and commenced intravenous (IV) hydrocortisone, IV maintenance fluids, and antibiotics. However, the constellation of signs and symptoms remained perplexing. Further tests revealed a large pericardial effusion, deep vein thrombosis, and nephritis. A multidisciplinary approach confirmed the diagnosis of systemic lupus erythematous (SLE), and the patient was successfully started on rituximab therapy within 5 days of admission. This case illustrates the importance of considering potential underlying diagnoses when assessing patients with hypothyroid crisis, especially when symptoms deviate from the typical clinical presentation. The timely recognition and management of this patient's underlying SLE were crucial in her recovery.
- Open Access
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , e4086-e4100
Phenotypic Variation and Pubertal Outcomes in Males and Females With 46,XY Partial Gonadal Dysgenesis
Background: 46,XY gonadal dysgenesis is classified as complete (CGD) or partial (PGD) subtypes. The phenotype of PGD and the long-term outcome is not clearly defined. Objective: To evaluate clinical features and pubertal outcome of PGD in a large cohort, using CGD as a comparator for diagnostic clarity. Methods: Patients with 46,XY GD were identified from the I-DSD Registry and data on phenotype, genetics, biochemistry, gonadal histology, and pubertal development were collated in 3 categories; CGD (n = 100), PGD assigned female (PGDf, n = 107), and male (PGDm, n = 103) at birth. Results: Most individuals with PGD presented with atypical genitalia in infancy, though, 18% of PGDf presented with delayed puberty and 8% with virilization. A genetic etiology was identified in 42% of the cohort, with common gene defects in SRY and WT1 in CGD and NR5A1 in PGD. Gonadal pre-/malignancy was found in 33.8% in CGD, 19.7% in PGDf, and 8.8% in PGDm. Among the PGDm (>13 years) with at least 1 gonad, 80% had spontaneous pubertal onset and 59% achieved Tanner G5 without hormone treatment. Labioscrotal gonads at presentation and testosterone response to human chorionic gonadotropin predicted onset of spontaneous puberty. In PGDf with gonads, 42% developed spontaneous virilization at puberty. Sex was reassigned in 16.1% and 5.3% of individuals with PGDf and PGDm, respectively. Conclusion: This study highlights the heterogeneous phenotype of PGD and the consequent diagnostic challenge. Many PGD patients with preserved gonads have the potential to develop puberty spontaneously, though further study is needed to determine the risk of developing gonadal tumors.
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , e4086-e4100
Open AccessPhenotypic Variation and Pubertal Outcomes in Males and Females With 46,XY Partial Gonadal Dysgenesis
Background: 46,XY gonadal dysgenesis is classified as complete (CGD) or partial (PGD) subtypes. The phenotype of PGD and the long-term outcome is not clearly defined. Objective: To evaluate clinical features and pubertal outcome of PGD in a large cohort, using CGD as a comparator for diagnostic clarity. Methods: Patients with 46,XY GD were identified from the I-DSD Registry and data on phenotype, genetics, biochemistry, gonadal histology, and pubertal development were collated in 3 categories; CGD (n = 100), PGD assigned female (PGDf, n = 107), and male (PGDm, n = 103) at birth. Results: Most individuals with PGD presented with atypical genitalia in infancy, though, 18% of PGDf presented with delayed puberty and 8% with virilization. A genetic etiology was identified in 42% of the cohort, with common gene defects in SRY and WT1 in CGD and NR5A1 in PGD. Gonadal pre-/malignancy was found in 33.8% in CGD, 19.7% in PGDf, and 8.8% in PGDm. Among the PGDm (>13 years) with at least 1 gonad, 80% had spontaneous pubertal onset and 59% achieved Tanner G5 without hormone treatment. Labioscrotal gonads at presentation and testosterone response to human chorionic gonadotropin predicted onset of spontaneous puberty. In PGDf with gonads, 42% developed spontaneous virilization at puberty. Sex was reassigned in 16.1% and 5.3% of individuals with PGDf and PGDm, respectively. Conclusion: This study highlights the heterogeneous phenotype of PGD and the consequent diagnostic challenge. Many PGD patients with preserved gonads have the potential to develop puberty spontaneously, though further study is needed to determine the risk of developing gonadal tumors.
- Open Access
- 23 October 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (3) , 743-754
Adjuvant Rituximab—Exploratory Trial in Young People With Graves Disease
Context: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). Objective: We explored whether rituximab (RTX), a B-lymphocyte–depleting agent, would increase remission rates when administered with a short course of ATD. Methods: This was an open-label, multicenter, single-arm, phase 2 trial in young people (ages, 12-20 years) with Graves hyperthyroidism. An A’Hern design was used to distinguish an encouraging remission rate (40%) from an unacceptable rate (20%). Participants presenting with Graves hyperthyroidism received 500 mg RTX and 12 months of ATD titrated according to thyroid function. ATDs were stopped after 12 months and primary outcome assessed at 24 months. Participants had relapsed at 24 months if thyrotropin was suppressed and free 3,5,3′-triiodothyronine was raised; they had received ATD between months 12 and 24; or they had thyroid surgery/radioiodine. Results: A total of 27 participants were recruited and completed the trial with no serious side effects linked to treatment. Daily carbimazole dose at 12 months was less than 5 mg in 21 of 27 participants. Thirteen of 27 participants were in remission at 24 months (48%, 90% one-sided CI, 35%-100%); this exceeded the critical value (9) for the A’Hern design and provided evidence of a promising remission rate. B-lymphocyte count at 28 weeks, expressed as a percentage of baseline, was related to likelihood of remission. Conclusion: Adjuvant RTX, administered with a 12-month course of ATD, may increase the likelihood of remission in young people with Graves hyperthyroidism. A randomized trial of adjuvant RTX in young people with Graves hyperthyroidism is warranted.
- 23 October 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (3) , 743-754
Open AccessAdjuvant Rituximab—Exploratory Trial in Young People With Graves Disease
Context: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). Objective: We explored whether rituximab (RTX), a B-lymphocyte–depleting agent, would increase remission rates when administered with a short course of ATD. Methods: This was an open-label, multicenter, single-arm, phase 2 trial in young people (ages, 12-20 years) with Graves hyperthyroidism. An A’Hern design was used to distinguish an encouraging remission rate (40%) from an unacceptable rate (20%). Participants presenting with Graves hyperthyroidism received 500 mg RTX and 12 months of ATD titrated according to thyroid function. ATDs were stopped after 12 months and primary outcome assessed at 24 months. Participants had relapsed at 24 months if thyrotropin was suppressed and free 3,5,3′-triiodothyronine was raised; they had received ATD between months 12 and 24; or they had thyroid surgery/radioiodine. Results: A total of 27 participants were recruited and completed the trial with no serious side effects linked to treatment. Daily carbimazole dose at 12 months was less than 5 mg in 21 of 27 participants. Thirteen of 27 participants were in remission at 24 months (48%, 90% one-sided CI, 35%-100%); this exceeded the critical value (9) for the A’Hern design and provided evidence of a promising remission rate. B-lymphocyte count at 28 weeks, expressed as a percentage of baseline, was related to likelihood of remission. Conclusion: Adjuvant RTX, administered with a 12-month course of ATD, may increase the likelihood of remission in young people with Graves hyperthyroidism. A randomized trial of adjuvant RTX in young people with Graves hyperthyroidism is warranted.